Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07125079 · ClinicalTrials.gov registry record
Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.
A clinical trial of ARDS (Acute Respiratory Distress Syndrome), sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 36
- Enrollment target
- 1
- Study location
NCT07125079: Recruiting study of ARDS (Acute Respiratory Distress Syndrome), sponsored by University of Pennsylvania.
NCT07125079 is a study of ARDS (Acute Respiratory Distress Syndrome) that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 36 participants, below the 300-participant average among 4 other ARDS (Acute Respiratory Distress Syndrome) trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07125079, a study of ARDS (Acute Respiratory Distress Syndrome), is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) is a condition where high levels of inflammation damage the lung. This is a highly morbid condition with no specific pharmacologic therapies. The investigators posit that ARDS is caused due to an exaggerated activation of immune cells and that blockade of this activation may reduce lung damage/injury and help in ARDS management and possibly recovery. To test this hypothesis, the investigators propose to generate an in vitro immune cell model and test a novel (reactive oxygen species) blocking agent PIP-2 on this model. The investigating team will obtain blood of ARDS patients and isolate immune cells (specifically peripheral blood mononuclear cells or PBMC) and monitor the activation of these cells and their blockade by PIP-2. This is entirely an in vitro study.
Primary Outcome
Peripheral Blood Mononuclear cells (PBMC) isolated
Conditions Studied
Study Locations (1)
Pennsylvania
- Hospital Of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-05-20 |
| Est. Completion | 2026-11-20 |
What NCT07125079 shows while recruiting
NCT07125079 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 300-participant average among 4 other ARDS (Acute Respiratory Distress Syndrome) trials with a reported enrollment target (88% lower).
The record links to 1 condition, with ARDS (Acute Respiratory Distress Syndrome) appearing as the primary indexed condition, and to 0 interventions.
NCT07125079 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07125079 about?
NCT07125079 is a clinical study titled "Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.". Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) is a condition where high levels of inflammation damage the lung. This is a highly morbid condition with no specific pharmacologic therapies. The investigators posit that ARDS is caused due to an exaggerated activation of immune ...
What is the current status of trial NCT07125079?
This trial is currently recruiting. The enrollment target is 36 participants. The study started on 2025-05-20. Estimated completion is 2026-11-20.
What conditions does trial NCT07125079 study?
This clinical trial studies the following conditions: ARDS (Acute Respiratory Distress Syndrome).
Who is sponsoring clinical trial NCT07125079?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07125079 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ARDS (Acute Respiratory Distress Syndrome)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
RECRUITING · Phase 2
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI